Larazotide Acetate
AT-1001 · INN-202
First-in-class tight junction peptide that reduces intestinal permeability (leaky gut) and zonulin-related inflammation.
Half-Life
~1–2 hours
MW
N/A
Amino Acids
N/A
Evidence
Clinical
Regulatory Status
Phase 3 clinical trials for celiac disease
In Plain English
Repairs the "door seals" between gut cells. When these tight junctions break down, unwanted molecules pass through (leaky gut); larazotide closes them back up. Phase 3 clinical trials for celiac disease with a good safety record.
Overview
Larazotide acetate (AT-1001) is an 8-amino acid peptide that acts as a tight junction regulator in the intestinal epithelium. It blocks the effects of zonulin and other tight junction disruptors, reducing intestinal permeability — commonly called "leaky gut." Has been in clinical trials for celiac disease and is investigated for IBS, gluten sensitivity, and general gut barrier dysfunction.
Common Formats
- Oral capsule (in trials)
- Injectable
Storage Notes
Lyophilized: refrigerate. Oral formulations are stable at room temperature per clinical packaging.
Looking for multi-compound protocols?
Browse educational protocol discussions that include Larazotide Acetate.
Related Compounds
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.